Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis

Company Overview

Mydecine Innovations Group Inc. is a biotechnology company focused on developing psychedelic-derived medicines and related treatment protocols for mental health and addiction disorders. Its work has centered primarily on psilocybin-based therapies, with an emphasis on standardized formulations, clinical research, and treatment approaches designed to support conditions such as post-traumatic stress disorder, depression, and substance-use disorders.

The company has historically advanced development programs including MYCO-001, a pharmaceutical-grade psilocybin formulation intended for controlled clinical use, as well as other investigational psychedelic compounds and delivery technologies. Mydecine has also pursued collaborations with academic and clinical research organizations to evaluate psychedelic-assisted therapies, including research related to smoking cessation and other behavioral-health applications.

Founded in Canada and associated with operations in the United States, Mydecine has focused its activities on the North American psychedelic-medicine market. Publicly reported leadership has included founder and former chief executive officer Josh Bartch, although the company’s management, programs, and operating status may have changed over time. Mydecine’s development efforts remain subject to clinical, regulatory, and commercial uncertainties typical of early-stage biotechnology companies.

Key Stats

• Today's Range: $0.73 to $0.73
• 50-Day Range: $0.73 to $1.10
• 52-Week Range: $0.01 to $2.04
• Volume: N/A
• Average Volume: 3,650 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/16/2021
• Today: 9/26/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:MYCOF
• CIK: N/A
• Web: www.newleafbrands.com
• Phone: (604) 687-2038
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A